Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable
Live moderated video webcast discussion between members of management and Key Opinion Leader, Jonathan Graf, MD. on Wednesday, October 28th at 4:00 PM ET
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that members of management will participate in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 4:00 PM ET.
Participating in the KOL Roundtable discussion will be Jed Latkin, Navidea’s Chief Executive Officer and Michael Rosol, Ph.D., Chief Medical Officer of Navidea. Joining the Navidea management team for the discussion will be Jonathan Graf, MD. Dr. Graf is Professor in the Department of Medicine at the University of California San Francisco (UCSF) in the division of rheumatology at Zuckerberg San Francisco General. He is board certified in rheumatology, receiving his MD degree from the University of Pennsylvania and completing his residency and fellowship training at the UCSF School of Medicine. He has been a practicing rheumatologist for nearly 20 years and co-founded the UCSF rheumatoid arthritis (RA) cohort in 2006. He is co-author on numerous publications in the field of rheumatology and has been an investigator on multiple clinical trials related to rheumatoid arthritis. He currently receives research support from Navidea as one of the lead investigators for the NAV3-31 trial in RA, and he has been involved in the design and execution of this and other clinical trials of Tilmanocept in RA.
A live video webcast of the KOL Roundtable will be available on the IR Calendar page of the Investors section of the Company’s website (www.navidea.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.
In addition to the KOL roundtable discussion, members of the management team will be available for one-on-one meetings with qualified members of the investment community. To schedule a one-on-one call with management, please submit a request through the conference website virtualinvestorco.com, or contact the conference at email@example.com. For more information about the event, please visit virtualinvestorco.com.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Navidea is not responsible for the contents of third-party websites.
Navidea Biopharmaceuticals, Inc.
Jed Latkin, CEO
Head of Strategy and Business Development
Source: Navidea Biopharmaceuticals, Inc.
Released October 22, 2020